Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.77)
# 92
Out of 5,180 analysts
44
Total ratings
67.35%
Success rate
37.5%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRXS NeurAxis | Maintains: Buy | $8 → $13 | $6.61 | +96.67% | 3 | Mar 20, 2026 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $30 → $35 | $22.58 | +55.00% | 8 | Mar 20, 2026 | |
| HROW Harrow | Maintains: Buy | $54 → $64 | $33.30 | +92.19% | 4 | Sep 23, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $5.77 | +142.63% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $4.21 | +208.79% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $5.60 | +96.43% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $6.64 | +65.66% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $3.83 | -21.67% | 1 | Jul 1, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $10.53 | +61.44% | 3 | Jun 9, 2025 | |
| MDWD MediWound | Initiates: Buy | $39 | $15.46 | +152.26% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $3.23 | +147.68% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $8.89 | +136.22% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $4.25 | +41.18% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $3.86 | +210.88% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $8.35 | +19.76% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.54 | +120.99% | 2 | Jul 11, 2023 |
NeurAxis
Mar 20, 2026
Maintains: Buy
Price Target: $8 → $13
Current: $6.61
Upside: +96.67%
Eton Pharmaceuticals
Mar 20, 2026
Maintains: Buy
Price Target: $30 → $35
Current: $22.58
Upside: +55.00%
Harrow
Sep 23, 2025
Maintains: Buy
Price Target: $54 → $64
Current: $33.30
Upside: +92.19%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $5.77
Upside: +142.63%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $4.21
Upside: +208.79%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $5.60
Upside: +96.43%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $6.64
Upside: +65.66%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $3.83
Upside: -21.67%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $10.53
Upside: +61.44%
MediWound
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $15.46
Upside: +152.26%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $3.23
Upside: +147.68%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $8.89
Upside: +136.22%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $4.25
Upside: +41.18%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $3.86
Upside: +210.88%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $8.35
Upside: +19.76%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.54
Upside: +120.99%